What 'They' Refers To in Lipitor Comparisons
No specific drug or treatment ("they") is named in the query, but Lipitor (atorvastatin) comparisons often involve statins like Crestor (rosuvastatin), Zocor (simvastatin), or generics. Clinical trials show Lipitor generally matches or exceeds rivals in lowering LDL cholesterol, the key metric for heart disease risk.[1]
How Lipitor Stacks Up Against Crestor
Crestor reduces LDL more at high doses (e.g., 40 mg Crestor drops LDL by 57% vs. 51% for 80 mg Lipitor in the STELLAR trial). But Lipitor wins on side effects and cost; Crestor raises diabetes risk more (odds ratio 1.25 vs. 1.05 for Lipitor in meta-analyses).[2][3] Real-world use favors Lipitor for its balance.
Lipitor vs. Other Statins Like Zocor or Pravachol
Lipitor outperforms Zocor (LDL drop: 51% vs. 38% at max doses) and Pravachol (51% vs. 34%) in head-to-head trials like CURVES. It also cuts heart events better in high-risk patients (PROVE-IT trial: 16% vs. 22% for pravastatin).[4]
Why Lipitor Became the Top-Selling Statin
Lipitor dominated (peak $13B/year sales) due to superior potency across doses, fewer muscle pains than simvastatin, and strong event reduction in TNT trial (22% relative risk drop vs. low-dose). Patents expired 2011, shifting to generics.[5]
Do Newer Drugs Beat Lipitor?
PCSK9 inhibitors like Repatha or Praluent lower LDL more (60%+ vs. Lipitor's 50%), but they're injectables, cost $14K/year, and suit only high-risk cases post-statin failure. Trials (FOURIER) show added event reduction, but statins like Lipitor remain first-line per guidelines.[6]
[1] NEJM - STELLAR Trial
[2] Lancet - Diabetes Risk Meta-Analysis
[3] JAMA - Statin Comparisons
[4] NEJM - CURVES
[5] DrugPatentWatch.com - Lipitor Patents
[6] NEJM - FOURIER Trial